Brain-Boosting Benefits of Natural Compounds for Alzheimer's-like Symptoms

Greg Howard
12th July, 2024

Brain-Boosting Benefits of Natural Compounds for Alzheimer's-like Symptoms

Image Source: Natural Science News, 2024

Key Findings

  • The study from Hamadan University of Medical Sciences explored the effects of DHEA and H. erinaceus mushroom extract on AD-like symptoms in male Wistar rats
  • Scopolamine significantly impaired memory and increased oxidative stress in the rats, mimicking AD symptoms
  • Treatment with DHEA and H. erinaceus improved memory, reduced oxidative stress, and increased BDNF levels, showing a synergistic neuroprotective effect
Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by cognitive decline, memory loss, and behavioral disorders. Traditional understanding attributes AD to amyloid proteinopathy, where abnormalities in protein folding and structure disrupt cellular functions[2]. This disorder is linked to metabolic dysfunctions, highlighting the importance of metabolomics in diagnosing and prognosing neurodegenerative diseases. Recent research has expanded to include the roles of neurotransmitter metabolism and genetic and epigenetic factors in AD[2]. Additionally, the cholinergic hypothesis, which focuses on the role of acetylcholine in memory and learning, has been a longstanding theory in understanding AD pathogenesis[3]. A recent study conducted by Hamadan University of Medical Sciences investigated the neuroprotective effects of Dehydroepiandrosterone (DHEA) and Hericium erinaceus (H. erinaceus) mushroom extract against scopolamine-induced AD-like symptoms in male Wistar rats[1]. This study aimed to explore potential therapeutic approaches to mitigate AD symptoms by leveraging the neurotrophic properties of these compounds. In this study, sixty-four male Wistar rats were divided into eight groups, with scopolamine (SCO) used to induce AD-like symptoms. SCO was administered at a dose of 1 mg/kg/day for 10 days. The treatment groups received DHEA (250 mg/kg/day) and/or H. erinaceus (300 mg/kg/day) orally for 14 days. Behavioral assessments were conducted using the Morris water maze (MWM) and novel object recognition tests to evaluate spatial and cognitive memory. Following these tests, brain tissue samples were collected for biochemical and histopathological analysis. The results demonstrated that SCO significantly impaired spatial and cognitive memory, as evidenced by the behavioral tests. Biochemically, SCO increased lipid peroxidation (LPO) levels, indicating oxidative stress, while reducing total antioxidant capacity (TAC), catalase activity (CAT), and brain-derived neurotrophic factor (BDNF) levels. These findings align with previous studies highlighting the role of BDNF in neuronal health and cognitive function[4]. BDNF is crucial for neuronal differentiation, cell survival, and synaptic function, and its downregulation is associated with cognitive decline in AD and other mental disorders[4]. Interestingly, the combination of DHEA and H. erinaceus showed higher efficacy in mitigating behavioral anomalies and improving antioxidant defenses and BDNF levels compared to either treatment alone. This suggests a synergistic effect between DHEA and H. erinaceus in enhancing neuroprotection. Histological examination corroborated these biochemical findings, showing reduced neurodegeneration in the treatment groups. The study's findings suggest that DHEA and H. erinaceus could serve as a beneficial concurrent therapy for treating AD-like symptoms. By improving antioxidant defenses and increasing BDNF levels, these compounds may help counteract the neurodegenerative processes associated with AD. This aligns with the broader understanding of AD pathogenesis, which involves metabolic dysfunctions and neurotransmitter imbalances[2][3]. In summary, this study from Hamadan University of Medical Sciences provides promising evidence for the neuroprotective effects of DHEA and H. erinaceus against scopolamine-induced AD-like symptoms. By enhancing antioxidant defenses and BDNF levels, these compounds offer a potential therapeutic approach to mitigate cognitive decline and neurodegeneration in AD. This research contributes to the ongoing exploration of novel treatments for AD, emphasizing the importance of targeting metabolic and neurotrophic pathways in combating this complex disease.

MedicineHealthAnimal Science

References

Main Study

1) Neuroprotective Effects of Dehydroepiandrosterone and Hericium erinaceus in Scopolamine-induced Alzheimer's Diseases-like Symptoms in Male Rats.

Published 11th July, 2024

https://doi.org/10.1007/s12013-024-01400-y

Related Studies

2) Metabolic disorder in Alzheimer's disease.

https://doi.org/10.1007/s11011-021-00673-z

3) Role of Cholinergic Signaling in Alzheimer's Disease.

https://doi.org/10.3390/molecules27061816

4) Involvement of brain-derived neurotrophic factor signaling in the pathogenesis of stress-related brain diseases.

https://doi.org/10.3389/fnmol.2023.1247422


Related Articles

An unhandled error has occurred. Reload 🗙